Royal London Asset Management Ltd. raised its stake in shares of Illumina, Inc. (NASDAQ:ILMN – Free Report) by 0.4% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 62,527 shares of the life sciences company’s stock after acquiring an additional 267 shares during the quarter. Royal London Asset Management Ltd.’s holdings in Illumina were worth $6,527,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds also recently made changes to their positions in ILMN. Trivant Custom Portfolio Group LLC increased its stake in Illumina by 166.7% in the first quarter. Trivant Custom Portfolio Group LLC now owns 200 shares of the life sciences company’s stock valued at $27,000 after acquiring an additional 125 shares during the period. Versant Capital Management Inc increased its stake in Illumina by 292.9% in the second quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company’s stock valued at $34,000 after acquiring an additional 246 shares during the period. Industrial Alliance Investment Management Inc. bought a new stake in Illumina in the second quarter valued at about $34,000. Massmutual Trust Co. FSB ADV increased its stake in Illumina by 86.8% in the first quarter. Massmutual Trust Co. FSB ADV now owns 284 shares of the life sciences company’s stock valued at $39,000 after acquiring an additional 132 shares during the period. Finally, Principal Securities Inc. bought a new stake in Illumina in the fourth quarter valued at about $51,000. Institutional investors own 89.42% of the company’s stock.
Illumina Trading Up 2.3 %
Shares of NASDAQ ILMN opened at $129.18 on Friday. The company’s 50 day simple moving average is $123.36 and its 200 day simple moving average is $120.96. Illumina, Inc. has a fifty-two week low of $89.00 and a fifty-two week high of $152.87. The firm has a market capitalization of $20.58 billion, a P/E ratio of -15.85 and a beta of 1.15. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.11 and a quick ratio of 0.86.
Analyst Upgrades and Downgrades
ILMN has been the topic of a number of analyst reports. Argus raised shares of Illumina from a “hold” rating to a “buy” rating and set a $150.00 target price on the stock in a research note on Wednesday, August 28th. Daiwa America raised shares of Illumina to a “strong-buy” rating in a research note on Friday, August 16th. StockNews.com assumed coverage on shares of Illumina in a research note on Thursday, August 29th. They set a “buy” rating on the stock. Barclays raised shares of Illumina from an “underweight” rating to an “equal weight” rating and set a $125.00 price objective on the stock in a research note on Wednesday, August 14th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Illumina from $130.00 to $125.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $151.05.
Check Out Our Latest Analysis on Illumina
About Illumina
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Recommended Stories
- Five stocks we like better than Illumina
- What to Know About Investing in Penny Stocks
- Powering Your Portfolio: The Utility Sector’s Electrifying Surge
- Basic Materials Stocks Investing
- Adobe Stock Builds Long-Term Value: Consider Buying on the Dip
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Albemarle Jumps as Lithium Stock Buying Frenzy Takes Off
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN – Free Report).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.